{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:42:35Z","timestamp":1762144955673,"version":"build-2065373602"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009558","name":"University Natural Science Research Project of Anhui Province","doi-asserted-by":"publisher","award":["2023AH051972"],"award-info":[{"award-number":["2023AH051972"]}],"id":[{"id":"10.13039\/501100009558","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2502700"],"award-info":[{"award-number":["2022YFC2502700"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018938","name":"Administration of Traditional Chinese Medicine of Jilin Province","doi-asserted-by":"publisher","award":["YB2020099"],"award-info":[{"award-number":["YB2020099"]}],"id":[{"id":"10.13039\/100018938","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82274339","81973658","82104487","81973658,82274339"],"award-info":[{"award-number":["82274339","81973658","82104487","81973658,82274339"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.ejphar.2025.177541","type":"journal-article","created":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T23:01:08Z","timestamp":1743116468000},"page":"177541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Discovery of cmpd D6 (FH-001) as a efficiency enhancement and myelosuppression degradation small-molecule fms-like tyrosine kinase 3 inhibitor for the treatment of FLT3-ITD positive acute myeloid leukemia"],"prefix":"10.1016","volume":"996","author":[{"given":"Yanan","family":"Qi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanyuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengting","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanmei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Tao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiwei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fangtian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ejphar.2025.177541_bib1","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41375-019-0694-3","article-title":"FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions","volume":"34","author":"Antar","year":"2020","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177541_bib2","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/ajh.25027","article-title":"FLT3 inhibitors in acute myeloid leukemia: choosing the best when the optimal does not exist","volume":"93","author":"Assi","year":"2018","journal-title":"Am. J. Hematol."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177541_bib3","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1002\/anie.201704146","article-title":"Deuterium- and tritium-labelled compounds: applications in the life sciences","volume":"57","author":"Atzrodt","year":"2018","journal-title":"Angew. Chem."},{"issue":"21","key":"10.1016\/j.ejphar.2025.177541_bib4","doi-asserted-by":"crossref","first-page":"7714","DOI":"10.1021\/acs.analchem.1c01076","article-title":"Monitoring deuterium uptake in single bacterial cells via two-dimensional Raman correlation spectroscopy","volume":"93","author":"Azemtsop Matanfack","year":"2021","journal-title":"Anal. Chem."},{"issue":"48","key":"10.1016\/j.ejphar.2025.177541_bib5","article-title":"Sulfonium salt reagents for the introduction of deuterated alkyl groups in drug discovery","volume":"62","author":"Ban","year":"2023","journal-title":"Angew. Chem."},{"key":"10.1016\/j.ejphar.2025.177541_bib6","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.2147\/DDDT.S379496","article-title":"Recent updates on the development of deuterium-containing drugs for the treatment of cancer","volume":"16","author":"Belete","year":"2022","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejphar.2025.177541_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106490","article-title":"Deuterated driven new chemical entities: an optimistic way to improve therapeutic efficacy","volume":"135","author":"Chandra Mouli","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"37","key":"10.1016\/j.ejphar.2025.177541_bib8","doi-asserted-by":"crossref","first-page":"14570","DOI":"10.1021\/jacs.9b08662","article-title":"Catalytic deuterium incorporation within metabolically stable \u03b2-amino C-H bonds of drug molecules","volume":"141","author":"Chang","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"3","key":"10.1016\/j.ejphar.2025.177541_bib9","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1182\/blood.2022016580","article-title":"PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371","volume":"141","author":"Chen","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejphar.2025.177541_bib10","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177541_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2025.177541_bib12","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2147\/DDDT.S138828","article-title":"Review of deutetrabenazine: a novel treatment for chorea associated with Huntington's disease","volume":"12","author":"Dean","year":"2018","journal-title":"Drug Des. Dev. Ther."},{"issue":"7","key":"10.1016\/j.ejphar.2025.177541_bib13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10393","key":"10.1016\/j.ejphar.2025.177541_bib14","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(23)00108-3","article-title":"Acute myeloid leukaemia","volume":"401","author":"DiNardo","year":"2023","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.ejphar.2025.177541_bib15","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1039\/C9SC05132E","article-title":"Formyl-selective deuteration of aldehydes with D(2)O via synergistic organic and photoredox catalysis","volume":"11","author":"Dong","year":"2019","journal-title":"Chem. Sci."},{"issue":"10388","key":"10.1016\/j.ejphar.2025.177541_bib16","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0140-6736(23)00464-6","article-title":"Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Erba","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejphar.2025.177541_bib17","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1001\/jamaneurol.2017.1352","article-title":"Safety of converting from tetrabenazine to deutetrabenazine for the treatment of chorea","volume":"74","author":"Frank","year":"2017","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177541_bib18","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1021\/jm4007998","article-title":"Using deuterium in drug discovery: leaving the label in the drug","volume":"57","author":"Gant","year":"2014","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejphar.2025.177541_bib19","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1080\/14656566.2020.1801637","article-title":"Quizartinib for the treatment of acute myeloid leukemia","volume":"21","author":"Garcia-Horton","year":"2020","journal-title":"Expet Opin. Pharmacother."},{"issue":"17","key":"10.1016\/j.ejphar.2025.177541_bib20","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1007\/s40265-017-0831-0","article-title":"Deutetrabenazine: a review in chorea associated with Huntington's disease","volume":"77","author":"Heo","year":"2017","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ejphar.2025.177541_bib21","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1152\/physrev.00029.2018","article-title":"FMS-Like tyrosine kinase 3\/FLT3: from basic science to clinical implications","volume":"99","author":"Kazi","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2025.177541_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.10","article-title":"Acute myeloid leukaemia","volume":"2","author":"Khwaja","year":"2016","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"17","key":"10.1016\/j.ejphar.2025.177541_bib23","doi-asserted-by":"crossref","first-page":"9448","DOI":"10.3390\/ijms25179448","article-title":"Enhancing therapeutic efficacy of FLT3 inhibitors with combination therapy for treatment of acute myeloid leukemia","volume":"25","author":"Leifheit","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"26","key":"10.1016\/j.ejphar.2025.177541_bib24","doi-asserted-by":"crossref","first-page":"3403","DOI":"10.1182\/blood-2017-05-782292","article-title":"Midostaurin approved for FLT3-mutated AML","volume":"129","author":"Levis","year":"2017","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejphar.2025.177541_bib25","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/s41557-021-00846-4","article-title":"Scalable and selective deuteration of (hetero)arenes","volume":"14","author":"Li","year":"2022","journal-title":"Nat. Chem."},{"issue":"24","key":"10.1016\/j.ejphar.2025.177541_bib26","doi-asserted-by":"crossref","first-page":"9625","DOI":"10.1021\/acs.jmedchem.5b01611","article-title":"Discovery of (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)-2-(dimethylamino)ethanone (CHMFL-FLT3-122) as a potent and orally available FLT3 kinase inhibitor for FLT3-ITD positive acute myeloid leukemia","volume":"58","author":"Li","year":"2015","journal-title":"J. Med. Chem."},{"issue":"5","key":"10.1016\/j.ejphar.2025.177541_bib27","doi-asserted-by":"crossref","first-page":"427","DOI":"10.23736\/S0026-4806.20.06989-X","article-title":"FLT3 inhibitors in the treatment of acute myeloid leukemia: current status and future perspectives","volume":"111","author":"Mosquera Orgueira","year":"2020","journal-title":"Minerva Med."},{"issue":"36","key":"10.1016\/j.ejphar.2025.177541_bib28","doi-asserted-by":"crossref","first-page":"26002","DOI":"10.1039\/D4RA05543H","article-title":"Enhanced oxidative stability of deuterated squalene: the impact of labelling extent on chemical resilience","volume":"14","author":"M\u00f6ller","year":"2024","journal-title":"RSC Adv."},{"issue":"11","key":"10.1016\/j.ejphar.2025.177541_bib29","doi-asserted-by":"crossref","first-page":"5276","DOI":"10.1021\/acs.jmedchem.8b01808","article-title":"Applications of deuterium in medicinal chemistry","volume":"62","author":"Pirali","year":"2019","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177541_bib30","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/1060028018797110","article-title":"Impact of deuterium substitution on the pharmacokinetics of pharmaceuticals","volume":"53","author":"Russak","year":"2019","journal-title":"Ann. Pharmacother."},{"issue":"6","key":"10.1016\/j.ejphar.2025.177541_bib31","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nbt0617-493","article-title":"First deuterated drug approved","volume":"35","author":"Schmidt","year":"2017","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.ejphar.2025.177541_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41392-023-01614-1","article-title":"Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort study","volume":"8","author":"Shao","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"issue":"10147","key":"10.1016\/j.ejphar.2025.177541_bib33","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ejphar.2025.177541_bib34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.ejphar.2025.177541_bib35","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2019000802","article-title":"circMYBL2, a circRNA from MYBL2, regulates FLT3 translation by recruiting PTBP1 to promote FLT3-ITD AML progression","volume":"134","author":"Sun","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.ejphar.2025.177541_bib36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1080\/13543776.2017.1378350","article-title":"Deuterated drugs; updates and obviousness analysis","volume":"27","author":"Timmins","year":"2017","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2","key":"10.1016\/j.ejphar.2025.177541_bib37","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3324\/haematol.2019.244186","article-title":"Selectively targeting FLT3-ITD mutants over FLT3-wt by a novel inhibitor for acute myeloid leukemia","volume":"106","author":"Wang","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.ejphar.2025.177541_bib38","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.1021\/acs.jmedchem.0c02247","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"issue":"9","key":"10.1016\/j.ejphar.2025.177541_bib39","doi-asserted-by":"crossref","first-page":"7197","DOI":"10.1021\/acs.jmedchem.4c00051","article-title":"Discovery of a novel orally bioavailable FLT3-PROTAC degrader for efficient treatment of acute myeloid leukemia and overcoming resistance of FLT3 inhibitors","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejphar.2025.177541_bib40","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1177\/1947601910396505","article-title":"Antileukemic effects of novel first- and second-generation FLT3 inhibitors: structure-affinity comparison","volume":"1","author":"Weisberg","year":"2010","journal-title":"Genes cancer"},{"issue":"1","key":"10.1016\/j.ejphar.2025.177541_bib41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s13045-018-0675-4","article-title":"FLT3 inhibitors in acute myeloid leukemia","volume":"11","author":"Wu","year":"2018","journal-title":"J. Hematol. Oncol."},{"issue":"8","key":"10.1016\/j.ejphar.2025.177541_bib42","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202204866","article-title":"Codelivery of BCL2 and MCL1 inhibitors enabled by phenylboronic acid-functionalized polypeptide nanovehicles for synergetic and potent therapy of acute myeloid leukemia","volume":"10","author":"Xie","year":"2023","journal-title":"Adv. Sci."},{"issue":"36","key":"10.1016\/j.ejphar.2025.177541_bib43","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.2174\/0929867330666221122123201","article-title":"Clinical application and synthesis methods of deuterated drugs","volume":"30","author":"Xu","year":"2023","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.177541_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2021.100905","article-title":"A review of FLT3 inhibitors in acute myeloid leukemia","volume":"52","author":"Zhao","year":"2022","journal-title":"Blood Rev."},{"issue":"21","key":"10.1016\/j.ejphar.2025.177541_bib45","doi-asserted-by":"crossref","first-page":"12403","DOI":"10.1021\/acs.jmedchem.0c00696","article-title":"Small-molecule fms-like tyrosine kinase 3 inhibitors: an attractive and efficient method for the treatment of acute myeloid leukemia","volume":"63","author":"Zhong","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejphar.2025.177541_bib46","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2147\/DDDT.S198950","article-title":"Quizartinib (AC220): a promising option for acute myeloid leukemia","volume":"13","author":"Zhou","year":"2019","journal-title":"Drug Des. Dev. Ther."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500295X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001429992500295X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:29:26Z","timestamp":1762144166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001429992500295X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":46,"alternative-id":["S001429992500295X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177541","relation":{},"ISSN":["0014-2999"],"issn-type":[{"type":"print","value":"0014-2999"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of cmpd D6 (FH-001) as a efficiency enhancement and myelosuppression degradation small-molecule fms-like tyrosine kinase 3 inhibitor for the treatment of FLT3-ITD positive acute myeloid leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2025.177541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"177541"}}